ClinicalTrials.gg
RecruitingNCT05391100Updated May 31, 2022

Screening of Patients With Rheumatoid Arthritis for Interstitial Lung Disease

An observational study in Rheumatoid Arthritis and Interstitial Lung Disease, sponsored by Polyclinic of the Hospitaller Brothers of St. John of God, Budapest. Recruiting at 3 sites in Hungary. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2022-05-31.

Sponsored by Polyclinic of the Hospitaller Brothers of St. John of God, Budapest · Observational

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
500
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 204 studies in Arthritis, Rheumatoid with a site in Hungary — 4 open to participants now, 11 under way, 2 of them phase 3. Arthritis, Rheumatoid · Hungary.

Planned enrollment
3rd of 11
500 · median 353
Started
2022
with 3 others
Observational
11 of 204
2 open now
Primary completion
2026-12
later than 4 of 10 live
Registered
191st of 204
by date

Among the 204 studies in Arthritis, Rheumatoid with a site in Hungary, this one is the 3rd largest by planned enrollment of the 11 observational ones that give a count, is one of 4 that started in 2022, is one of 11 observational ones, reaches primary completion later than 4 of the 10 other live ones, and was the 191st registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 204 studies in Arthritis, Rheumatoid with a site in Hungary are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Hungary have not opened yet or have stopped. Only those recruiting at a site in Hungary →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 204 studies in Arthritis, Rheumatoid with a site in Hungary, or all of them as a file.
02

Study summary

The quantitative and qualitative analysis of RA lung involvement in the Hungarian population

Read the detailed description

Interstitial lung disease (ILD) accounts for a significant proportion of mortality and morbidity in rheumatoid arthritis (RA). The aim of this prospective longitudinal study is to asess the interstitial lung involvement in Hungarian rheumatoid arthritis patients. Laboratory markers, X-ray based imaging methods, pulmonological functional tests, QOL questionnaire and sleep quality assessement questionnaire are used to estimate the interstitial lung disease. Also smaller cross-sectional studies about the imaging parameters and a national register is planned to be created based on these data.

03

Conditions studied

  • Rheumatoid Arthritis
  • Interstitial Lung Disease

Keywords

  • rheumatoid arthritis
  • Interstitial Lung Disease
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

RA patients with regular follow-ups at Polyclinic of Hospitaller Brothers of St. John of God, Budapest

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of RA

Exclusion criteria

Exclusion Criteria:

  • pregnancy, breastfeeding
  • previous diagnosis of ILD, lung cancer, registered lung infection in the last 2 months
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Prevalence of ILD

    detection of ILD with imaging methods

    Time frame: From baseline to at least 5 years

  2. pattern of ILD

    to characterize the ILD patterns based on imaging methods

    Time frame: From baseline to at least 5 years

Secondary outcomes

  1. Correlation with biomarkers

    correlation of the imaging results with respiratory function, disease activity and laboratory markers

    Time frame: From baseline to at least 2 years

07

Study locations

3 of 3 sites recruiting
  • Buda Hospital of the Hospitaller Order of Saint John of God
    Budapest, 1023, Hungary
    Recruiting
    • Kinga Fritsch, MD · Contact
    • Judit Majnik, MD PhD · Contact
    • György Nagy, MD PhD · Sub investigator
    • Dóra Sárvári, MD · Sub investigator
    • Tímea Petri · Sub investigator
  • Medical Imaging Centre, Semmelweis University
    Budapest, 1082, Hungary
    Recruiting
    • Nikolett Marton, MD, PhD · Contact
    • János Gyebnár, MD · Contact
    • Pal Maurovich-Horvat, MD PhD MPH · Sub investigator
    • Judit Simon, MD · Sub investigator
    • Ádám Domonkos Tárnoki, MD PhD · Sub investigator
    • Dávid László Tárnoki, MD PhD · Sub investigator
    • László Szakács, MD · Sub investigator
    • Hanna Balogh, MD · Sub investigator
    • Leila Szeibel, MD · Sub investigator
    • Tamas Purczel, MD · Sub investigator
    • Tamas Munkacsi, MD · Sub investigator
    • Nora Kerkovits, MD · Sub investigator
    • Klaudia Borbely, MD · Sub investigator
    • Csenge Poka, MD · Sub investigator
  • Department of Pulmonology, Semmelweis University Faculty of Medicine
    Budapest, 1083, Hungary
    Recruiting
    • Veronika Müller, MD PhD · Contact
    • Alexandra Nagy · Sub investigator
    • Nóra Tóth · Sub investigator
    • Tamás Nagy · Sub investigator
08

References and documents

Publications

  • Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol. 2013 May;25(3):360-6. doi: 10.1097/BOR.0b013e32835f693f. PubMed 23425964 ↗
  • Dai Y, Wang W, Yu Y, Hu S. Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology, pathogenesis and management. Clin Rheumatol. 2021 Apr;40(4):1211-1220. doi: 10.1007/s10067-020-05320-z. Epub 2020 Aug 13. PubMed 32794076 ↗
  • Avouac J, Amrouche F, Meune C, Rey G, Kahan A, Allanore Y. Mortality profile of patients with rheumatoid arthritis in France and its change in 10 years. Semin Arthritis Rheum. 2017 Apr;46(5):537-543. doi: 10.1016/j.semarthrit.2016.10.007. Epub 2016 Oct 29. PubMed 27908535 ↗
  • England BR, Hershberger D. Management issues in rheumatoid arthritis-associated interstitial lung disease. Curr Opin Rheumatol. 2020 May;32(3):255-263. doi: 10.1097/BOR.0000000000000703. PubMed 32141954 ↗
  • Hodnett PA, Naidich DP. Fibrosing interstitial lung disease. A practical high-resolution computed tomography-based approach to diagnosis and management and a review of the literature. Am J Respir Crit Care Med. 2013 Jul 15;188(2):141-9. doi: 10.1164/rccm.201208-1544CI. PubMed 23672718 ↗
  • Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest. 2009 Nov;136(5):1397-1405. doi: 10.1378/chest.09-0444. PubMed 19892679 ↗
  • Salvatore M, Henschke CI, Yip R, Jacobi A, Eber C, Padilla M, Knoll A, Yankelevitz D. JOURNAL CLUB: Evidence of Interstitial Lung Disease on Low-Dose Chest CT Images: Prevalence, Patterns, and Progression. AJR Am J Roentgenol. 2016 Mar;206(3):487-94. doi: 10.2214/AJR.15.15537. Epub 2015 Dec 23. PubMed 26700157 ↗
  • Ley S, Fidler L, Schenk H, Durand M, Marras T, Paul N, Shapera S, Mittoo S. Low dose computed tomography of the lung for detection and grading of interstitial lung disease: A systematic simulation study. Pulmonology. 2021 Jan-Feb;27(1):14-25. doi: 10.1016/j.pulmoe.2020.06.004. Epub 2020 Jun 24. PubMed 32591280 ↗
  • Hata A, Yanagawa M, Honda O, Miyata T, Tomiyama N. Ultra-low-dose chest computed tomography for interstitial lung disease using model-based iterative reconstruction with or without the lung setting. Medicine (Baltimore). 2019 May;98(22):e15936. doi: 10.1097/MD.0000000000015936. PubMed 31145365 ↗
  • National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug 4;365(5):395-409. doi: 10.1056/NEJMoa1102873. Epub 2011 Jun 29. PubMed 21714641 ↗
  • Kauczor HU, Baird AM, Blum TG, Bonomo L, Bostantzoglou C, Burghuber O, Cepicka B, Comanescu A, Couraud S, Devaraj A, Jespersen V, Morozov S, Nardi Agmon I, Peled N, Powell P, Prosch H, Ravara S, Rawlinson J, Revel MP, Silva M, Snoeckx A, van Ginneken B, van Meerbeeck JP, Vardavas C, von Stackelberg O, Gaga M; European Society of Radiology (ESR) and the European Respiratory Society (ERS). ESR/ERS statement paper on lung cancer screening. Eur Respir J. 2020 Feb 12;55(2):1900506. doi: 10.1183/13993003.00506-2019. Print 2020 Feb. PubMed 32051182 ↗
  • Peelen DM, Zwezerijnen BGJC, Nossent EJ, Meijboom LJ, Hoekstra OS, Van der Laken CJ, Voskuyl AE. The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients. Rheumatology (Oxford). 2020 Jun 1;59(6):1407-1415. doi: 10.1093/rheumatology/kez483. PubMed 31642912 ↗
  • Nagy A, Nagy T, Kolonics-Farkas AM, Eszes N, Vincze K, Barczi E, Tarnoki AD, Tarnoki DL, Nagy G, Kiss E, Maurovich-Horvat P, Bohacs A, Muller V. Autoimmune Progressive Fibrosing Interstitial Lung Disease: Predictors of Fast Decline. Front Pharmacol. 2021 Dec 22;12:778649. doi: 10.3389/fphar.2021.778649. eCollection 2021. PubMed 35002713 ↗
  • Barczi E, Nagy T, Starobinski L, Kolonics-Farkas A, Eszes N, Bohacs A, Tarnoki AD, Tarnoki DL, Muller V. Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival. Thorac Cancer. 2020 Jul;11(7):1911-1917. doi: 10.1111/1759-7714.13481. Epub 2020 May 13. PubMed 32401433 ↗
  • Croia C, Bursi R, Sutera D, Petrelli F, Alunno A, Puxeddu I. One year in review 2019: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 2019 May-Jun;37(3):347-357. Epub 2019 May 10. PubMed 31111823 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Dec 2026, 58 months after the start.

Of 235 non-industry observational studies under Arthritis, Rheumatoid, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 122. This study's planned 58 months is above that.

Counting every sponsor, half of 390 studies reached it within 50 months; a quarter within 25 and three quarters within 113.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2022
First posted
May 25, 2022
StartActual
Feb 1, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
May 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05391100
Lead sponsor
Polyclinic of the Hospitaller Brothers of St. John of God, Budapest
Collaborators
Medical Imaging Centre- Semmelweis University, Faculty of Medicine, Department of Pulmonology, Semmelweis University Faculty of Medicine
Responsible party
dr.Kinga Fritsch (MD, Polyclinic of the Hospitaller Brothers of St. John of God, Budapest) — Principal investigator
First posted
May 25, 2022
Start date
Feb 1, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 31, 2022

Study contacts

Kinga Fritsch, MD
Contact
kflinta@hotmail.com
+36302892319
Judit Majnik, MD PhD
Contact
judit@majnik.hu
+36306637976
Judit Majnik, MD PhD
principal investigator

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion